Latest filing published 19 Dec 2007 for Ocata Therapeutics, Inc., €6,927.
Insider track record
No signal scores available.
Jonathan F. Atzen: trading record in brief
Filings by Jonathan F. Atzen span 2 companies, the busiest being Genesis Bioventures Inc and Ocata Therapeutics, Inc. Over a trading history stretching from 5 February 2007 to 14 December 2007, the count stands at 7 filings.
On the market, this insider has only sold: 6 sales, €10k in total. Other entries cover 1 share grant.
The latest filing, published on 19 December 2007, reports an open-market sale of €6,927 in Ocata Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 11 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jonathan F. Atzen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 50,000 shares@ US$0.20Common StockSEC:0001179110-07-023811:0
- 5,000 shares@ US$0.125Common StockSEC:0001077048-07-000210:0
- 10,000 shares@ US$0.10Common StockSEC:0001077048-07-000210:1
- 5,000 shares@ US$0.11Common StockSEC:0001077048-07-000210:2
- 10,000 shares@ US$0.12Common StockSEC:0001077048-07-000210:3
- 10,000 shares@ US$0.12Common StockSEC:0001077048-07-000210:4
- 50,000 sharesCommon StockSEC:0001179110-07-003161:0
7 of 7 declarations